Pieris Pharmaceuticals (NASDAQ:PIRS) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report sent to investors on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Down 3.1 %

NASDAQ:PIRS opened at $10.90 on Wednesday. Pieris Pharmaceuticals has a 52-week low of $10.60 and a 52-week high of $80.80. The stock’s 50 day moving average price is $13.17 and its 200 day moving average price is $14.30. The company has a market capitalization of $14.39 million, a PE ratio of -0.91 and a beta of 0.55.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Friday, March 29th. The biotechnology company reported ($4.00) earnings per share (EPS) for the quarter. The business had revenue of $1.30 million for the quarter. Pieris Pharmaceuticals had a negative return on equity of 52.88% and a negative net margin of 39.71%.

Institutional Investors Weigh In On Pieris Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in PIRS. Summit Trail Advisors LLC purchased a new position in shares of Pieris Pharmaceuticals during the first quarter worth about $26,000. CM Management LLC grew its stake in shares of Pieris Pharmaceuticals by 18.1% in the 3rd quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock valued at $194,000 after purchasing an additional 99,400 shares during the last quarter. Finally, Acadian Asset Management LLC grew its stake in shares of Pieris Pharmaceuticals by 64.8% in the 3rd quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock valued at $286,000 after purchasing an additional 378,339 shares during the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.